Real world evidence is using data collected from a variety of sources to help determine treatment approaches to improve patient health.  Data can include electronic medical records, health registries, and administrative claims data generated outside of a randomized controlled trial.  Data from these sources provides important information about patient experience and treatment implementation. 

To be used as evidence, these data must be compiled and evaluated to address a specific research question that can be valuable to health system decision-makers, researchers, healthcare providers, regulators and the healthcare industry, to provide the evidence needed for effective decision-making and improved patient care.  Read about some examples of Janssen’s investments in real world evidence below:

The Johnson & Johnson Alberta Health Innovation Partnership

The Johnson & Johnson Alberta Health Innovation Partnership (JAHIP) is a collaboration between the Alberta Government’s Ministry of Economic Development and Trade, Alberta Health Services, Janssen Inc., and the University Hospital Foundation. 

JAHIP’s primary goal is to support innovation and improve patient and health system outcomes by focusing resources on the development of real world evidence in Alberta to make better-informed healthcare decisions.

The first project will look at reimbursement criteria for patients with schizophrenia being treated with long-acting injectable therapies, while considering the cost-effectiveness of and the delivery models for these therapies.

We anticipate that Alberta-specific real world evidence arising from this project will support the health ministry’s reimbursement recommendations and help ensure patients with schizophrenia get the medicines they need when they need them.

Health Innovation Partnership with Memorial University of Newfoundland

The Janssen and Newfoundland and Labrador Health Innovation Partnership (JANL-HIP) will focus on identifying priorities and undertaking real world evidence projects in complex conditions that are highly prevalent across the province.

Janssen will work with Memorial University of Newfoundland to leverage research leading to better decision-making and healthcare improvements for patients and the residents of Newfoundland and Labrador.

The JANL-HIP collaboration also includes representation from the Government of Newfoundland and Labrador’s Ministry of Health and Community Services, Ministry of Tourism, Culture, Industry and Innovation, Eastern Health and the Newfoundland and Labrador Centre for Health Information.